Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CpG-D35
Therapeutic Area: Infections and Infectious Diseases Product Name: CpG-D35
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Drugs for Neglected Disease Initiative
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2020
Details:
As part of this partnership, Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides, which provides a strong immunostimulatory effects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SARS-CoV-2 mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: LSP
Deal Size: $38.1 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 15, 2020
Details:
Proceeds of the financing will fund continued development and commercialization of proprietary mRNA technologies and a range of therapeutic products.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibody-based drug
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
Details:
The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
